| Literature DB >> 33428398 |
Rubén Varela-Fernández1,2, Xurxo García-Otero1,3, Victoria Díaz-Tomé1, Uxía Regueiro2, Maite López-López2, Miguel González-Barcia4, María Isabel Lema5, Francisco Javier Otero-Espinar1,6.
Abstract
This research study describes the design, optimization, and characterization of two different types of chitosan-based nanoparticles as novel drug delivery systems of a protein drug, lactoferrin. A preclinical consistent base was obtained for both nanosystems, being considered as the first pharmacological treatment for keratoconus as an alternative to current invasive clinical methods. Both types of nanoparticles were obtained via the ionotropic gelation technique. The size and morphology of the nanoparticles were studied as a function of the preparation conditions. A mean size of 180.73 ± 40.67 nm, a size distribution [polydispersity index (PDI)] of 0.170 ± 0.067, and positive ζ-potential values, ranging from 17.13 to 19.89 mV, were achieved. Lactoferrin was successfully incorporated into both types of nanocarriers. In vitro release profiles showed a lactoferrin enhanced, prolonged, and controlled delivery from the polymeric matrix. These formulations also demonstrated no stability or cytotoxicity problems, as well as appropriate mucoadhesive properties, with a high permanence time in the ocular surface. Thus, both types of nanoparticles may be considered as nanocarriers for the controlled release of lactoferrin as novel topical ophthalmic drug delivery systems.Entities:
Keywords: chitosan; keratoconus; lactoferrin; nanoparticles; protein nanocarriers; sulfobutylether-β-cyclodextrin; topical ophthalmic administration; tripolyphosphate
Mesh:
Substances:
Year: 2021 PMID: 33428398 DOI: 10.1021/acsami.0c18926
Source DB: PubMed Journal: ACS Appl Mater Interfaces ISSN: 1944-8244 Impact factor: 9.229